James B. Lucot, Ph.D.
Campus Address: 230 Health Sciences
Phone: (937) 775-3700
Fax: (937) 775-7221
Biology/Psychology, B.S. (1973), University of Pittsburgh, Pittsburgh, PA
Neurobiology, Ph.D. (1977), University of North Carolina, Chapel Hill, NC
Pharmacology and Toxicology, Postdoctoral (1977-1980), University of Chicago, Chicago, IL
- Intersection of toxicology and neuroscience at the level of behavior and neurochemistry
- Investigations into the co-morbidity of diabetes and psychiatric disorders
- Applying neurobehavioral assessment, neurochemical analysis and measurement of catecholamines in urine to characterize animal models of a wide range of disorders
My research approach is to evaluate the interactions between behavior, drugs, and brain chemistry. This approach provides the flexibility to undertake a wide range of projects, to pursue interesting findings, and join in collaborative research. The laboratory is currently working with multiple researchers to characterize knockout models using the research techniques available in my laboratory. These studies expand the knowledge to be gained from such models without requiring additional subjects because they can be conducted in the same animals being used for the primary purpose of the experiment. The results extend the knowledge base, raise new hypothesis and can generate additional components to grant proposals based on the results. The approach can also be used to provide standardized proof of efficacy for tests of novel therapies.
I have collaborative projects using an animal model of type-2 diabetes. We have discovered that there is an age-dependent change in behaviors associated with specific psychiatric disorders and that the brain chemical function is consistent with the behavioral changes. We are pursuing this finding by testing hypothesis regarding the biological basis for these changes to lead to alternative methods for treating psychiatric disorders in diabetic patients. Other work is directed at evaluating the consequences of the absence of a subtype of potassium/chloride receptor.
Lucot, J.B. Antiemetic effects of flesinoxan in cats: Comparisons with 8-hydroxy-2-(di-n-propylamine) tetralin. Eur. J. Pharmacol., 253:53-60, 1994.
Dubovicky, M., S. Paton, M. Morris, M. Mach, J.B. Lucot. Effects of combined exposure to pyridostigmine bromide and shaker stress on acoustic startle response, pre-pulse inhibition and open field behavior in mice. J. Appl. Tox, 27:276-283, 2007.
Mach, M., R.D. Grubbs, W.A. Price, M. Nagoaka, M. Dubovicky and J.B. Lucot. Delayed effect of subacute low-dose exposure to sarin combined with chronic intermittent shaker stress in mice. J. Appl. Tox., 14:28(2) 132-129, 2007.
Mauck, B.S., S.J.Paton, J.B. Lucot, R.D. Grubbs. Subcutaneous exposure to carbamate acetycholinesterase inhibitors does not induce apoptosis in mouse brain. J. Med. Chem. Biol. Rad. Defense, 6, 2008.
Garrett, T.L., C.M. Rapp, R.D. Grubbs, J.J. Schlager, and J.B. Lucot. A murine model for sarin exposure using the carboxylesterase inhibitor CBDP. Neurotoxicology, 2010, In press.
Sharma, A.N, K.M. Elased, T.L. Garrett, J.B. Lucot. Neurobehavioral deficits in db/db diabetic mice. Physiol. Behav., 2010, In Press.
Mauck, B., J.B. Lucot, S. Paton, R.D. Grubbs. Cholinesterase Inhibitors and Stress: Effects on Brain Muscarinic Receptor Density in Mice. Neurotoxicology, 2010, In Press.
Sharma, A.N, K.M. Elased, J.B. Lucot. Brain region-specific alterations in monoamine processing in db/db mice. In preparation for Physiology and Behavior, 2010.
Oswal, D.P., M. Morris, J.B. Lucot. Effect of low-dose sarin exposure on the neurochemistroy of different brain structures in mice. In preparation, 2010.
Joshi, K., C.R. Rapp, T.L. Garrett, M. Davidson, D.R. Cool, J.J. Schlager, and J.B. Lucot. The effect of 8-OH-DPAT on neurodegeneration after sarin exposure. Submitted to Neurotoxicology.